| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/14/2010 | EP2205637A1 Il-23 antibodies |
| 07/14/2010 | EP2205636A2 Human gm-csf antigen binding proteins |
| 07/14/2010 | EP2205635A1 Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| 07/14/2010 | EP2205634A2 Anti-neublastin antibodies and uses thereof |
| 07/14/2010 | EP2205633A1 New antibodies specific of the -amyloid peptides and their uses as diagnostic agents or drugs |
| 07/14/2010 | EP2205632A2 Use of anti-amyloid beta antibody in ocular diseases |
| 07/14/2010 | EP2205631A2 Humanized antibody |
| 07/14/2010 | EP2205630A1 Antibody against anthrax toxins |
| 07/14/2010 | EP2205627A1 Anticomplement polypeptides of ixodes ricinus |
| 07/14/2010 | EP2205277A1 Novel antibody therapies |
| 07/14/2010 | EP2205276A2 Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| 07/14/2010 | EP2205274A2 Compositions comprising yersinia pestis antigens |
| 07/14/2010 | EP2205273A1 Use of modified cells for the treatment of multiple sclerosis |
| 07/14/2010 | EP2205272A2 Molecular adjuvant |
| 07/14/2010 | EP2205258A1 Methods and structural conformations of antibody preparations with increased resistance to proteases |
| 07/14/2010 | EP2205256A2 Reagents for inducing an immune response |
| 07/14/2010 | EP2205228A2 Patch for cutaneous application, which comprises a hydrophile powder |
| 07/14/2010 | EP2205077A1 Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| 07/14/2010 | EP2205071A1 Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
| 07/14/2010 | EP1863530B1 Methods for damaging cells using effector functions of anti-gfra1 antibodies |
| 07/14/2010 | EP1734995B1 Monoclonal antibodies to hepatocyte growth factor |
| 07/14/2010 | EP1535927B1 Hbv precore protein capable of forming particles |
| 07/14/2010 | EP1418948B1 Replicating adenovirus vectors |
| 07/14/2010 | EP1278824B1 Clearance of ras-mediated neoplastic cells from mixed cellular compositions using reovirus |
| 07/14/2010 | EP1222226B1 Highly-neutralized ethylene copolymers and their use in golf balls |
| 07/14/2010 | EP1183332B1 Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142 |
| 07/14/2010 | EP1080211B1 Method of producing thy-a-deficient strains of vibrio cholerae, such strains and their use |
| 07/14/2010 | EP1079859B1 Bifunctional molecules and therapies based thereon |
| 07/14/2010 | EP0652771B2 Tetanus vaccine production |
| 07/14/2010 | CN101778867A Compositions and methods for treating pancreatic tumors |
| 07/14/2010 | CN101778641A Preventive/remedy for cancer |
| 07/14/2010 | CN101778640A antibody formulations |
| 07/14/2010 | CN101776680A Schistosoma japonicum fluke resistance medicine effect target and medicine sieving method |
| 07/14/2010 | CN101775399A Asia1 type multi-epitope recombinant vaccine of bovine foot-and-mouth disease viruses and preparation method thereof |
| 07/14/2010 | CN101775375A Preparation method of recombinant adeno-associated viruses containing EB virus latent membrane protein 1 and 2 genes and application thereof |
| 07/14/2010 | CN101775372A Anti-testicle-protein hT279 antibody or antibody fragment and application thereof |
| 07/14/2010 | CN101775371A Anti-testicle-protein hTSC29 antibody or antibody fragment and application thereof |
| 07/14/2010 | CN101773669A HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 07/14/2010 | CN101773668A Antivirus associated protein and application thereof |
| 07/14/2010 | CN101773667A Preparation method for vaccine of porcine circovirus II |
| 07/14/2010 | CN101773666A Therapeutic anticancer vaccine and preparation thereof |
| 07/14/2010 | CN101117627B Pig epidemic diarrhea virus attenuated vaccine strain and uses thereof |
| 07/13/2010 | US7754867 Contain an Fc part derived from human origin and do not bind complement factor C1q; for inflammatory and thrombotic disorders such as critical limb ischemia or peripheral arterial occlusive disease; atherosclerosis, thrombosis, restenosis, asthma, arthritis |
| 07/13/2010 | US7754859 Targeted binding agents directed to PDGFR-alpha and uses thereof |
| 07/13/2010 | US7754858 Antibodies to tumor necrosis factor receptor associated factor polypeptides |
| 07/13/2010 | US7754856 Human sodium-dependent bile acid transporter proteins |
| 07/13/2010 | US7754853 Tumor necrosis factors (TNF); site-directed mutagenesis, genetic deletions; monoclonal antibodies with decreased immunogenicity and lymphocyte epitopes; major histocompatibility complex binding ligands; for treatment of rheumatoid arthritis and Crohn's disease |
| 07/13/2010 | US7754734 Administering one or more rapamycin derivatives (including rapamycin and 40-O-(2-hydroxy)ethyl-rapamycin); lymphocytic leukemia, lymphoma, Epstein-Barr virus, inhibiting graft rejection and metastasis; drug screening |
| 07/13/2010 | US7754482 expanding a population of CD25+CD4+ Treg cells by contacting the population with artificial antigen presenting cells (aAPCs) comprising a K562 cell; for development of novel therapeutics where activation and expansion of a T cell can provide a benefit |
| 07/13/2010 | US7754464 Cellular permissivity factor for viruses and uses thereof |
| 07/13/2010 | US7754449 Human papilloma virus treatment |
| 07/13/2010 | US7754430 Papilloma virus capsomere vaccine formulations and methods of use |
| 07/13/2010 | US7754420 genetic engineering of a cyanovirin; gene therapy; exogenous gene expression; use alone or in combination with antiviral agents such as AZT; AIDS therapy |
| 07/13/2010 | US7754228 Cytotoxic T-cell epitopes from Chlamydia |
| 07/13/2010 | US7754227 Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine |
| 07/13/2010 | US7754226 Comprising peptidyl-prolyl isomerase (PPI) polypeptides of group C and G streptococci; an amino acid sequence that is 90% identical to the amino acid sequence of SEQ ID NO: 11.; immunogens; vaccines;kits; pharyngitis, scarlet fever, impetigo, cellulitis or erysipelas;toxic shock syndrome; pneumonia |
| 07/13/2010 | US7754225 administering a conjugate of an isolated S. epidermidis antigen containing a 1,3-poly(glycerol phosphate) polymer chain and N-acetyl-glucosamine residues attached to the 2-position of the glycerol, and such antigen binds with antibodies to S. epidermidis to cure staphylococcal infected patient |
| 07/13/2010 | US7754224 Nucleotide sequences coding glycoprotein for use in vaccine development for prevention of ehrichlia infection; serodiagnostic agents |
| 07/13/2010 | US7754223 Piscirickettsia salmonis antigens and use thereof |
| 07/13/2010 | US7754222 Safe mutant viral vaccines |
| 07/13/2010 | US7754221 A recombinant Lister vaccinia virus, comprising a modified thymidine kinase gene, a modified hemagglutinin gene, and a modified F3gene or locus, each gene or locus is denactivated; the virus comprises heterologous nucleic acid encoding a gene; antitumor,carcinogenic, -proliferative agents; nontoxic |
| 07/13/2010 | US7754219 by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen |
| 07/13/2010 | US7754218 Vaccines comprising aluminum adjuvants and histidine |
| 07/13/2010 | US7754217 HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 07/13/2010 | US7754216 treating inflammatory conditions by modulating kallikrein 6 protease activity |
| 07/13/2010 | US7754215 used for the prevention of acute arterial thrombotic syndromes; do not directly block the GPIb-vWF axis or the GPIIb-IIIa receptor; restenosis, hyperplasia after agioplasty, atherectomy or arterial stenting |
| 07/13/2010 | US7754214 Using DCRS5 cytokine receptors modulators to treat psoriasis and atopic dermatitis |
| 07/13/2010 | US7754213 High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
| 07/13/2010 | US7754212 Contraceptives based on SP22 and SP22 antibodies |
| 07/13/2010 | US7754211 Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens |
| 07/13/2010 | US7754210 Antibodies binding to RSATEEEPPNDD or DVEDSYGQQWTYEQR peptides (or isoforms/derivatives thereof) of alpha-subunit of (Na++K+)-ATPase, are highly inotropic; both antibodies and peptides are important for treatment of heart failure |
| 07/13/2010 | US7754207 administering IL-16 antagonist; pneumonitis, fibrosis and sarcoidosis |
| 07/13/2010 | US7754206 reducing the size of a solid tumor expressing CD44 using Notch4 antagonist |
| 07/13/2010 | US7754201 Method of vaccination through serotype rotation |
| 07/13/2010 | CA2538124C Biological active coating components, coatings, and coated surfaces |
| 07/13/2010 | CA2447030C Immune modulation device for use in animals |
| 07/13/2010 | CA2324289C Combined vaccine compositions |
| 07/13/2010 | CA2297345C Novel antigenic class of avian reoviruses |
| 07/13/2010 | CA2286873C Dendritic cell hybrids |
| 07/13/2010 | CA2262893C Peptides responsive to antibodies against a consensus peptide of the cs4-cfa/i family proteins |
| 07/13/2010 | CA2259724C Monoclonal antibody which is specific for activated coagulation factor vii, and its use |
| 07/13/2010 | CA2183564C Methods for altering fertility |
| 07/13/2010 | CA2176742C Composition for the in vivo production of therapeutic products |
| 07/09/2010 | CA2648602A1 Method of treating pregnant cows and/or heifers |
| 07/08/2010 | WO2010078580A2 Immunotherapy for contact dermatitis using co-signal regulation |
| 07/08/2010 | WO2010078518A1 Anti-herpes simplex virus antibodies and methods of use thereof |
| 07/08/2010 | WO2010078478A1 Tissue adjuvants and medical products including the same |
| 07/08/2010 | WO2010078329A1 Methods and compositions for the treatment of pathogenic diseases |
| 07/08/2010 | WO2010078242A1 Injectable botulinum toxin formulations |
| 07/08/2010 | WO2010078027A1 Chlamydia antigens and uses thereof |
| 07/08/2010 | WO2010077986A2 Production of viral vaccine |
| 07/08/2010 | WO2010077894A2 Methods of inhibiting quiescent tumor proliferation |
| 07/08/2010 | WO2010077854A1 High affinity human antibodies to pcsk9 |
| 07/08/2010 | WO2010077717A1 Modified rsv f proteins and methods of their use |
| 07/08/2010 | WO2010077712A1 Bovine respiratory syncytial virus virus-like particle (vlps) |
| 07/08/2010 | WO2010077634A1 Anti-pd-l1 antibodies and their use to enhance t-cell function |
| 07/08/2010 | WO2010077473A2 Monoclonal antibodies that react with the capsule of bacillus anthracis |
| 07/08/2010 | WO2010076618A1 Combination gas vaccines and therapeutics |
| 07/08/2010 | WO2010076537A1 Immunoglobulin g composition |
| 07/08/2010 | WO2010076496A1 Use of an immunoglobulin g (igg) concentrate depleted of anti-a and anti-b antibodies for treating neonatal jaundice caused by maternal-foetal incompatibility with respect to the abo system |